Dorota Zgodka is a pharmaceutical and healthcare executive, currently Principal at human-centric research and service solutions design strategic consulting company. She brings a three-sided perspective and over 20 years of experience from pharma industry, umbrella patient advocacy and HTA organizations, throughout the medicine value chain and care pathway, in senior leadership roles spanning: strategy, commercial, policy and advocacy, value and access, R&D, business development, and portfolio management.
A champion of value-based health care, innovative partnerships, and new ways of working, partner to all key stakeholder groups and multiple coalitions. She has served as a board trustee and strategic counsel of diverse for-profit and non-profit organizations, including public-private partnerships, pharmaceutical companies, industry associations, HTAi research organization, umbrella patient organizations and advocacy groups. She is a Steering Committee member of the HTAi Rare Disease Interest Group and member of the Patient and Citizen Involvement Group, co-chairing also the project on new paradigms in evidence and fair value assessment of rare disease technologies; rare disease expert of EURORDIS’ Newborn Screening Working Group; member of Advocacy and Population Needs Group of EURORDIS’ Mental Health and Wellbeing Partnership Network; consortium adviser of SCREEN4CARE, the European public-private partnership; member of the Patient Focused Medicine Development global coalition; board trustee of FH Europe, the Pan-European Patient Network; former inherited cardiovascular and metabolic diseases patient expert and strategic counsel of NOVARTIS’ Access Advisory Board and NOVARTIS’ European Patient Advocacy Leadership Council.
She holds scientific PhD and the post-doctoral experience from the Drug Discovery Center in Athens, GA, USA, and executive business education from the London Business School, UK.
